Assessing the Performance of a Computer-Based Policy Model of HIV and AIDS by Rydzak, Chara Elaine et al.
 
Assessing the Performance of a Computer-Based Policy Model of
HIV and AIDS
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Rydzak, Chara E., Kara L. Cotich, Paul E. Sax, Heather E. Hsu,
Bingxia Wang, Elena Losina, Kenneth A. Freedberg, Milton C.
Weinstein, and Sue J. Goldie. 2010. Assessing the Performance of
a Computer-Based Policy Model of HIV and AIDS. PLoS ONE
5(9): e12647.
Published Version doi:10.1371/journal.pone.0012647
Accessed February 19, 2015 8:26:26 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:4882985
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAAssessing the Performance of a Computer-Based Policy
Model of HIV and AIDS
Chara E. Rydzak
1,2, Kara L. Cotich
2, Paul E. Sax
3, Heather E. Hsu
1,4, Bingxia Wang
4, Elena Losina
4,5,6,
Kenneth A. Freedberg
1,2,4,6,7, Milton C. Weinstein
2, Sue J. Goldie
2*, for the CEPAC Investigators
"
1Harvard Medical School, Boston, Massachusetts, United States of America, 2Department of Health Policy and Management, Harvard School of Public Health, Boston,
Massachusetts, United States of America, 3Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, United States
of America, 4Division of General Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 5Department of
Orthopedic Surgery, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, 6Departments of Biostatistics and Epidemiology, Boston University
School of Public Health, Boston, Massachusetts, United States of America, 7Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital,
Boston, Massachusetts, United States of America
Abstract
Background: Model-based analyses, conducted within a decision analytic framework, provide a systematic way to combine
information about the natural history of disease and effectiveness of clinical management strategies with demographic and
epidemiological characteristics of the population. Among the challenges with disease-specific modeling include the need to
identify influential assumptions and to assess the face validity and internal consistency of the model.
Methods and Findings: We describe a series of exercises involved in adapting a computer-based simulation model of HIV
disease to the Women’s Interagency HIV Study (WIHS) cohort and assess model performance as we re-parameterized the
model to address policy questions in the U.S. relevant to HIV-infected women using data from the WIHS. Empiric calibration
targets included 24-month survival curves stratified by treatment status and CD4 cell count. The most influential
assumptions in untreated women included chronic HIV-associated mortality following an opportunistic infection, and in
treated women, the ‘clinical effectiveness’ of HAART and the ability of HAART to prevent HIV complications independent of
virologic suppression. Good-fitting parameter sets required reductions in the clinical effectiveness of 1
st and 2
nd line HAART
and improvements in 3
rd and 4
th line regimens. Projected rates of treatment regimen switching using the calibrated cohort-
specific model closely approximated independent analyses published using data from the WIHS.
Conclusions: The model demonstrated good internal consistency and face validity, and supported cohort heterogeneities
that have been reported in the literature. Iterative assessment of model performance can provide information about the
relative influence of uncertain assumptions and provide insight into heterogeneities within and between cohorts.
Description of calibration exercises can enhance the transparency of disease-specific models.
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Introduction
Over the past fifteen years there has been remarkable progress
in the treatment of HIV-1 infection.[1–4] Where highly potent
combination antiretroviral therapy (HAART) is accessible, HIV
has become a chronic treatable disease, albeit complex and costly,
requiring lifelong management.[1,5] There are a number of
clinical and policy questions that remain to be addressed in HIV,
ranging from the optimal time to begin antiretroviral treatment to
how best to increase access to care and improve adherence to
antiretroviral therapy. Unfortunately, no single study can include
all possible strategies, and the rapid evolution in treatment options
poses a challenge for trial-based investigations to keep pace with
the questions to be answered. Even when clinical trials are
conducted, they are often limited in their length of follow-up and
rely on intermediate outcomes.[6–14]
Model-based analyses, conducted within a decision analytic
framework, provide a systematic way to combine information
about the natural history of disease, efficacy of different treatment
regimens, and effectiveness of clinical management strategies with
other relevant demographic and epidemiological characteristics of
the target population.[15–17] When used within a decision-
analytic framework, models can extend knowledge from empirical
studies to other situations and can be used to evaluate alternative
strategies not feasible to explore in a clinical trial. When the data
are insufficient to support traditional forms of investigation,
models offer a practical framework for managing uncertainty via
sensitivity and ‘‘what-if’’ analysis.
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12647Over the past 10 years, the ‘‘Cost-effectiveness of Preventing
AIDS Complications (CEPAC)’’ model has been used to conduct
analyses intended to guide HIV clinical decision-making and policy
formulation in a variety of settings.[18–30] The model has been
iteratively revised as new data become available, both about the
disease itself, and the wide array of new treatment options. Persistent
challenges with any simulation model of a complex disease include
the detail required to reflect a realistic representation of the disease
process, the pace at which data become available, and the need to
continuously revisit assumptions in the context of new information.
As the complexity of a model increases, so will the requirements for
parameters. Input values are almost never available for all
parameters, and analysts rely on approaches ranging from expert
assumptions with careful sensitivity analyses to conducting calibra-
tion exercises that involve fitting model output to epidemiological
data in order to inform uncertain parameter estimates. Regardless of
the method used to parameterize the model, decision analysts seekto
assess parameter uncertainty and to explore the relative influence of
uncertain assumptions made. While sensitivity analyses to address
parameter uncertainty are included in most decision analyses,
analysts often conduct many exploratory analyses to assess the
influenceofmodel assumptions.Whendataareavailable toallowfor
suchexercises, they provide an opportunity to assess the model’s face
validity and internal consistency. However, even when conducted,
often these exercises are unable to be included in peer-reviewed
publications due to space limitations.
In this paper, we describe a series of exercises that were
conducted as we re-parameterized the CEPAC model to address
clinical and policy questions in the United States relevant to HIV-
infected women. This process required that data be extracted from
the Women’s Interagency HIV Study (WIHS) and adapted to a
format required by the model.[31–34] We used this effort to assess
the internal consistency of the model, identify influential
assumptions on model outcomes, and assess the external
consistency of the model with independent published analyses.
This paper describes the process and steps taken to do so.
Methods
The Cost-Effectiveness of Preventing AIDS Complications
(CEPAC) model is a 1
st-order (i.e., patient level) Monte Carlo
simulation model of HIV disease, and has been previously
described.[18–30] Disease progression in the model is characterized
as a sequence of monthly transitions from one ‘‘health state’’ to
another. Health states, descriptive of each patient’s true underlying
health, are defined by current and maximum HIV RNA, current
and lowest CD4 lymphocyte count, and current and prior
opportunistic infections. Drawing from an initial distribution of
specified demographic (age, sex) and clinical characteristics (CD4
count, HIV RNA level, history of opportunistic infection), the
model simulatesa cohortof individualpatients whoseclinical course
is tracked from model entry until death. A random number
generator and a set of estimated probabilities are used to determine
the sequence of clinical pathways that a given patient follows, while
a runningtallyis maintained ofallacute clinical events,thelengthof
time spent in each health state, and the cost associated with each
health state. Upon the patient’s death, summary statistics for that
individual arerecorded. One millionpatients aresimulated, one ata
time, in order to provide stable estimates of long-term outcomes for
each strategy. Model outcomes include intermediate outcomes such
as number and type of opportunistic infections, time spent on
treatment, and proportion alive each month, as well as long-term
aggregate outcomes such as life expectancy, quality-adjusted life
expectancy, and lifetime costs.
The progression of underlying HIV disease is modeled as a
function of both HIV RNA and CD4 cell counts. Opportunistic
infections are based on previous analyses of primary and published
data, and are differentiated according to severity as previously
described.[28,31–35] Treatment with HAART and successful
HIV RNA suppression result in a CD4 cell count rise, which in
turn produces a reduction in the risk of acute opportunistic
infections and death. HAART efficacy is modeled as an initial
probability of virologic suppression and subsequent monthly
probability of failure. For individuals on HAART who experience
virologic failure, the CD4 cell count remains stable for a specified
number of months, after which the CD4 cell count declines at a
monthly rate governed by the current viral load. An independent
protective effect of HAART is modeled as a multiplier which
decreases the incidence of opportunistic infections and AIDS-
related mortality in patients with virologic failure who remain on
HAART (herein referred to as the ART effect).[36,37]
Details regarding the analysis of data used in the CEPAC model
may be found in prior publications [2–4,18–30,36–38]; in most of
these analyses the natural history of disease progression in the
absence of treatment was based on data from the Multicenter AIDS
Cohort Study (MACS)—a longitudinal study of HIV/AIDS in gay
andbisexual meninitiatedin1984 and consistingofa cohortof over
5,600 men.[2–4,35,38–40] To address clinical and policy questions
in the U.S. relevant to HIV-infected women, we extracted data
from the Women’s Interagency HIV Study (WIHS), a longitudinal
study of HIV disease begun in 1993 and consisting of data from
approximately 3,000 HIV-infected women and 1,000 uninfected
women.[31–34] Using survival data from the WIHS, we established
empiric calibration targets that included 24-month survival curves
based on untreated HIV-infected women, according to starting
CD4cell count.These servedas a comparison against whichmodel-
generated survival curves could be evaluated.
Comparison of Natural History Model Projected Survival
to Empiric Data
To compare natural history model projected survival with
empiric data, we first generated Kaplan-Meier survival curves
using the natural history model parameterized with data from the
MACS. Second, we generated survival curves using the natural
history model parameterized with new data from the WIHS. Third,
we identified several uncertain assumptions relevant to natural
history, which were varied extensively in sensitivity analysis. These
assumptions, listed in order of subjective uncertainty, included the
following: (a) the probability of ‘‘chronic AIDS’’ death (i.e., deaths
occurring after 30 days of an OI diagnosis) is higher compared to
the probability of AIDS death given no OI history (herein referred
to as attribution); (b) the incidence of OIs and the probability of OI-
related mortality change over time with disease progression (as
defined by CD4 cell count and viral load) and differ by gender; (c) in
the absence of HAART, the rate of CD4 decline is conditional on
HIV RNA, and differs by gender. The parameters governing these
assumptions were systematically varied and model-projected
survival was compared with empiric 24-month survival from the
WIHS. Consistency between model projections and empiric data
was assessed by visually comparing the average model outcomes
withthe meansand the 95% confidence intervals (CI) of the empiric
survival data.
Comparison of Treatment Model Projected Survival to
Empiric Data
Survival data were obtained from women in the WIHS who
initiated HAART between 1998 and 2002 and were followed for
HIV Policy Model Performance
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until a woman’s CD4 count reached 200/ml or less, and that 4
distinct HAART regimens were available.[41] We assumed that
women who survived over the long-term would have had access to
more recent regimens as they became available during their
treatment, but would likely have experienced decreased efficacy
due to previous exposure to other earlier HAART regimens. We
explored a variety of scenarios designed to capture the
heterogeneities of treatment response given different levels of
previous exposure to non-HAART monotherapy or combination
antiretroviral therapy for women in the WIHS cohort, as well as
differences in adherence and loss to follow-up. Kaplan-Meier
survival curves were constructed from model simulation outputs
and visually compared to WIHS empirical survival curves for
HIV-infected women receiving HAART. In addition, the
goodness of fit was quantitatively evaluated by comparing the
sum of the absolute differences between model estimates at 6, 12,
18 and 24 months with the mean empiric data at the same time
points. Parameter sets were then ranked based on the value of the
sum of the absolute differences for all of the time points; those
parameter sets with the lowest values (i.e., smallest difference
compared to the empiric data) were considered to be more
consistent with the empiric survival data.
We explored the influences of changes in assumptions and
treatment parameter values on the consistency between the model-
projected survival and the empiric data. We identified several key
uncertain treatment-related parameters and assumptions which we
varied systematically, first one at a time and then in combination,
to assess their impact on model-projected survival (Table 1).
These included: (a) ‘clinical effectiveness’ of HAART (a function of
regimen efficacy, tolerance without major toxicity, adherence, and
personal choice to remain on treatment); (b) the magnitude of an
independent protective effect of HAART on opportunistic
infection incidence and AIDS mortality in patients with virologic
failure (herein referred to as the ART effect); (c) monthly CD4 cell
gains while on effective HAART; (d) the risk of early and late
treatment failure (where ‘‘early treatment failure’’ is defined as
regimen failure within the first 6 months of treatment with a
Table 1. Summary of selected treatment parameter values.
Variable or Assumption Initial Value Exploratory Range
HAART Efficacy (% Viral Load Suppression at 24 weeks)
EFV + AZT + 3TC 75% +/2 10% to 90%*
IDV + AZT (or d4T) + 3TC 60% (10% increments)
LPV/r + TDF + FTC + AZT 61%
ENF + OBR 32.7%
OBR (2 PIs + 2 NRTIs) 15%
Mean CD4 Gain/ml on Successful Treatment over first 12 months (SD)
Time Period 1 (months 1–2)
EFV + AZT + 3TC 68.81 (17.20) +/2 20% to 50%
IDV + AZT (or d4T) + 3TC 25.02 (6.26)
LPV/r + TDF + FTC + AZT 68.71 (17.18)
ENF + OBR 75.63 (18.91)
OBR (2 PIs + 2 NRTIs) 26.04 (6.51)
Time Period 2 (months 3–12)
EFV + AZT + 3TC 3.60 (0.90) +/2 20% to 50%
IDV + AZT (or d4T) + 3TC 1.31 (0.33)
LPV/r + TDF + FTC + AZT 3.60 (0.90)
ENF + OBR 3.96 (0.99)
OBR (2 PIs + 2 NRTIs) 1.36 (0.34)
Late Treatment Failure*
Pooled Monthly Probability 0.021099 None, 50% decrease to 200% increase
ART Effect{
CD4 ,50/ml 0.78 No ART effect, 0.78, 0.66, 0.54, 0.25
CD4 .50/ml 0.66 No ART effect, 0.78, 0.66, 0.54, 0.25
Assumptions
Delay in CD4 decline 1 year None, 2 years
Force failure 10 years 5, 15 and 20 years, Never
3TC = lamivudine; ART = antiretroviral therapy; AZT = zidovudine; ddI = didanosine; d4T = stavudine; EFV = efavirenz; ENF = enfuvirtide; FTC = emtricitabine;
HAART = highly active antiretroviral therapy; IDV = indinavir; LPV/r = lopinavir/ritonavir; NRTI = nucleoside reverse transcriptase inhibitors; NNRTI = non-nucleoside
reverse transcriptase inhibitors; OBR = optimized background antiretroviral regimen; SD = standard deviation; TDF = tenofovir.
*Note that treatment efficacy was capped at a maximum of 95% and a minimum of 5% regardless of regimen; in some instances this resulted in a percent changei n
efficacy that was less than the original stated change.
{The ART effect is defined as an independent protective effect of HAART and is modeled as a multiplier which decreases the incidence of opportunistic infections and
AIDS-related mortality in patients with virologic failure who remain on HAART.
doi:10.1371/journal.pone.0012647.t001
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monthly probability of treatment failure after initially successful
virologic suppression after the first 6 months of treatment); (e)
estimates of the delay in CD4 count decline following virologic
rebound associated with HAART failure; and (f) the maximum
duration of treatment efficacy in patients who did not experience
virologic failure.
Assessment of Consistency with Independent Analyses of
Data from the WIHS
By calibrating to cohort-specific data, we implicitly assumed the
‘clinical effectiveness’ of HAART reflects several factors (e.g.,
regimen efficacy, tolerance, and adherence). We assessed the
consistency of the calibrated model to independent analyses that
used a distinct subset of data from the WIHS not used in the initial
parameterization. We identified a published analysis[34] that
provided estimates of time on treatment and time to regimen
switch from women treated with HAART in the WIHS cohort; in
that study, ‘switching’ was defined to include participants who
discontinued or switched to a less intense regimen as well as those
switching to a different HAART regimen for any reason.[34]
Using the calibrated model we then conducted simulations with
the 50 best-fitting parameter sets to compare the estimated median
time on treatment and time to regimen switch with these published
cohort-specific data.[34]
Finally, to gain insight into the nature of the differences between
the WIHS cohort[34] and the clinical trials from which we obtain
treatment efficacy data to use in contemporary analyses, we
conducted simulations using the baseline model prior to
calibration, and tracked all women who switched from a given
regimen due to virologic failure as well as women who experienced
either minor or nonfatal major toxicity. We compared the model-
generated estimated ‘switching’ (from either virologic failure or
single drug switch due to intolerance or toxicity) to the published
estimates of time on treatment and time to regimen switch
reported from the WIHS (Kirstein et al.),[34] after removing
women who discontinued HAART, to make the model-generated
estimate of ‘switching’ more comparable. For this exercise we
assumed that approximately 1 in 4 women with minor toxicity
would discontinue treatment.[42]
Influential Factors on Projection of Long-Term Out-
comes. We compared the differences between estimates of life
expectancy derived from the model calibrated to the 24-month
short-term data (using the mean of the 50 best-fitting sets) to those
generated using the original model parameters prior to calibra-
tion. We also explored uncertain variables hypothesized to be
influential on long-term outcomes, including probability of late
treatment failure (defined as the monthly probability of treat-
ment failure after initially successful virologic suppression), an
independent protective effect of HAART on mortality in patients
with virologic failure (i.e., ART effect), delay in CD4 decline
following virologic rebound associated with HAART failure,
availability of 5 sequential lines of HAART rather than 4 lines,
and major HAART toxicity.
Data
Cohort characteristics and natural history parameter values for
HIV-infected women in the WIHS cohort who did not receive
HAART are provided in Supporting Information S1.[31]
Natural history inputs estimated from the WIHS dataset were
derived using similar linear interpolation methods as those used to
develop analogous estimates for the MACS dataset.[31–34]
Corresponding data are provided for the MACS cohort in
Supporting Information S1.[2–4,35,38–40]
The definition of HAART was based on guidelines from the
Department of Health and Human Services/Kaiser and the
International AIDS Society—USA Panel guidelines.[1,34,41]
Women were considered to be on HAART if their regimen
consisted of one of the following: ‘‘two or more nucleoside reverse
transcriptase inhibitors (NRTIs) in combination with at least one
protease inhibitor (PI) or one non-nucleoside reverse transcriptase
inhibitor (NNRTI); one NRTI in combination with at least one PI
and at least one NNRTI; a regimen containing ritonavir and
saquinavir in combination with one NRTI and no NNRTIs; or an
abacavir-containing regimen of three or more NRTIs in the
absence of both PIs and NNRTIs.’’ [1,34,41]
HAART regimens used in this analysis are representative of
those available during the treatment era between 1998 and 2002
during which a subset of women in the WIHS initiated treatment;
these regimens are based on those described by Walensky and
colleagues.[43] HAART efficacy estimates were based on a
threshold of suppression of HIV RNA ,400 copies/mla t2 4
weeks after initiation of a given HAART regimen. A threshold of
,400 copies/ml was used, as this reflected the minimum threshold
level of virus detectable by most tests used during that time-
frame.[38,44,45] Efficacy estimates used intent-to-treat data for all
regimens.[42,46–49] Estimates of total mean CD4 count gains
while on specific HAART regimens incorporated loss-to-follow up
in the cohort.[42,46–49] Supporting Information S1 provides
assumptions about HAART efficacy, OI prophylaxis efficacy and
risk of toxicity. [33,42,46–58]
Estimates of regimen-specific monthly probabilities of late
failure after initial successful virologic suppression were calculated
using efficacy estimates for 24 weeks and the percent suppressed at
the furthest reported time point after 24 weeks (usually 48 or 96
weeks). Regimen-specific late failure probabilities were then used
to calculate the pooled probability of late regimen failure after
initial successful suppression.[42,46–49] Estimates of the ART
effect were based on values reported by Kousignian and
colleagues.[50] Individuals with a CD4 count ,50/ml had an
ART effect value of 0.78 while those with a CD4 count $50/ml
had an ART effect value of 0.66; these amounted to a decrease in
the magnitude of risk of 22% and 34%, respectively.[50] The
plausible range explored included no ART effect (no risk
reduction), an ART effect of 0.54 based on a study by Cole et
al. (46% reduction in the probability of OI’s and chronic AIDS
death), and an ART effect of 0.25 (75% reduction in risk).[51]
Results
Performance of the Natural History Model
Figure 1, Part A, shows the model-estimated survival of those
members of the WIHS cohort who did not receive HAART, using
natural history input parameters derived from the MACS. With
the exception of the highest CD4 stratum (CD4 $350/ml), the
model underestimated survival for individuals with initial CD4 cell
counts ,350/ml, particularly as follow-up time increased.
Figure 1, Part B, shows the model-estimated survival using
natural history input parameters derived from the WIHS. The re-
parameterized model more closely approximates the empiric data
for the three lowest CD4 strata (generally within the 95% CI)
although the model continues to marginally underestimate mean
survival in CD4 strata 50–199/ml and 200–349/ml. Model-
projected survival in the highest CD4 stratum ($350/ml) is more
significantly underestimated, with a better visual fit achieved using
natural history inputs derived from the MACS.
Better consistency between model-projected survival and
empiric data was achieved with adjustment of CD4 stratum-
HIV Policy Model Performance
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probability of AIDS-related mortality in patients with a history
of previous opportunistic infections (attribution) by 25% for CD4
50–199/ml and 50% for CD4 $200/ml resulted in better
estimation of the empiric survival data (Figure 1, Part C). These
adjusted values for attribution remained within 95% CI of the
original estimates. Enhanced consistency between model-projected
survival and empiric survival was not achieved with only changes
in OI incidence or plausible changes in CD4 cell decline.
Performance of the Treatment Model
For members of the WIHS cohort who received HAART,
model-projected survival over 12 months and at 24 months was
higher than the mean empiric survival. An initial exploratory set of
one-way sensitivity analyses were conducted to provide insight into
the magnitude of influence of each uncertain assumption. The
most influential of these one-way sensitivity analyses included
reductions in the (1) ‘clinical effectiveness’ of HAART (a function
of regimen efficacy, tolerance, adherence, and personal choice to
remain on treatment); (2) CD4 cell gain on HAART; and (3) ART
effect. None of the one-way sensitivity analyses achieved
simultaneous consistency with both 12- and 24-month outcomes
(Supporting Information S1 provides a summary of changes in
‘clinical effectiveness’). In general, scenarios most consistent with
the empiric data at 12 months underestimated survival at 24
months, while those most consistent with the empiric data at 24
months overestimated survival at 12 months.
Using insights from the one-way sensitivity analyses, a series of
additional multi-way sensitivity analyses allowed assumptions to
vary by regimen (e.g., 50% decrease in CD4 cell gain on 1
st and
2
nd line HAART but an increase in CD4 cell gain for 3
rd and 4
th
line HAART) and also allowed changes in two or more variables
simultaneously (e.g., 50% reduction in ‘clinical effectiveness’ of
HAART and 50% decrease in CD4 gain). Selected results are
shown in Supporting Information S1. In general, multi-way
sensitivity analyses allowed less extreme (and more plausible
changes) in individual variables while providing better visual fits to
the data.
Varying each of the uncertain assumptions individually, in
combination, and according to HAART regimen, generated more
than 1500 unique combinations of parameters for each CD4
stratum. Including all 1500 unique combinations, we calculated
the absolute difference between the mean 6, 12, 18 and 24 month
model-projected and empiric survival. For each of the CD4 strata,
we selected the 50 parameter sets with the smallest absolute
difference between the mean of the empiric data and the mean of
the projected model outcomes at 6, 12, 18 and 24 months. Herein
we refer to these 50 parameter sets as the ‘‘best-fitting’’ parameter
sets. Figure 2 shows the model-projected 24-month survival for
the best-fitting sets versus the empiric data for CD4 50–199/ml
(Figure 2, Part A) and CD4 ,50/ml( Figure 2, Part B).
For CD4 50–199/ml( Figure 2, Part A), the 50 best-fitting
parameter combinations that produced the best estimates of 6, 12,
18 and 24 month survival (i.e., minimized the difference between
model output and empiric survival across all four time points) were
similar, in that the ‘clinical effectiveness’ of 1
st and 2
nd line
HAART was reduced, while that of 3
rd and 4
th line HAART was
increased in combination with similar directional changes in CD4
gain estimates. Specifically, across the 50 best-fitting parameter
sets, there was a 2- to 3-fold increase in failure or discontinuation
rate for HAART lines 1 and 2, corresponding to a 70% reduction
in the average overall virologic suppression in the cohort. Note
that this average overall virologic suppression corresponds to that
of a heterogeneous cohort; there are some members who are non-
adherent, some who elect to change to a less efficacious non-
HAART regimen, and some who discontinue HAART. In
contrast, across the 50 best-fitting parameter sets, the clinical
effectiveness of 3
rd and 4
th line HAART was increased by 40% to
75%. In the majority of best-fitting parameter sets, CD4 gain was
reduced by 20% to 50% for 1
st and 2
nd line HAART, while CD4
gain was increased by 20% to 50% for lines 3 and 4. Compared to
previous one-way analyses, runs using combinations of less
extreme value changes across multiple parameters provided
improved fits of the empiric data. For CD4 ,50/ml( Figure 2,
Part B) the 50 best-fitting parameter combinations that produced
the best estimates of 6, 12, 18 and 24 month survival were similar
to those in the higher CD4 strata.
Assessment of Consistency with Independent Analyses of
Data from the WIHS
Using the model calibrated to the WIHS cohort, we estimated
percentage who switched from their initial 1
st and 2
nd line
HAART regimens within one year and the estimated median time
to 3
rd line HAART; using the 50 best-fitting parameter sets.
Model-projected ‘switching’ (1
st or 2
nd line HAART) was 65.8% in
the first year, and the estimated median time to 3
rd line HAART
was 28.3 months. In comparison, Kirstein et al.[34] reported that
among women initiating HAART in the WIHS cohort, 65% (95%
confidence interval [CI]: 62%, 68%) ‘switched’ (for any reason)
their initial HAART regimen within one year of initiation, and
that the median time on 1
st and 2
nd line HAART was 26 months
(Table 2, left side).[34,42]
Using the baseline model prior to calibration, the estimated
switching as a result of virologic failure with 1
st and 2
nd line
HAART was 25% to 40%; if we assumed 25% of women who
experienced minor toxicity and all women with nonfatal major
toxicity required a single drug change, the model-generated
‘‘estimated switching’’ ranged from 28.25% to 45.25%. These
results were consistent with the published data; when we excluded
women who discontinued HAART, Kirstein reported between
21.4% and 45.6% experienced a ‘switch’ in their HAART
regimen (Table 2, right side).[34,42]
Figure 1. Base case natural history data with WIHS cohort characteristics. Part A of Figure 1 shows the model-estimated survival of the
WIHS cohort using natural history input parameters derived from the MACS. With the exception of the highest CD4 stratum (CD4 $350/ml), the model
underestimates survival for individuals with initial CD4 cell counts ,350/ml, particularly as follow-up time increased. Part B of Figure 1 shows the
base-case model-estimated survival using natural history input parameters derived from the WIHS. The re-parameterized model more closely
approximates the empiric data for the three lowest CD4 strata (generally within the 95% CI), although the model continues to marginally
underestimate mean survival in CD4 strata CD4 50–199/ml and CD4 200–349/ml. Model-projected survival in the highest CD4 stratum ($350/ml) is
more significantly underestimated, with a better visual fit achieved using natural history inputs derived from the MACS (Figure 1, Part A). Part C of
Figure 1 shows the impact of adjustment of CD4-specific attribution on model-projected survival. Part C of Figure 1 demonstrates that better
consistency between model-projected survival and empiric data was best achieved with adjustment of CD4 stratum-specific attribution. Specifically,
reduction of the incrementally increased probability of AIDS-related mortality in patients with a history of previous opportunistic infections
(attribution) by 25% for CD4 50–199/ml and 50% for CD4 strata $200/ml resulted in better estimation of the empiric survival data.
doi:10.1371/journal.pone.0012647.g001
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PLoS ONE | www.plosone.org 6 September 2010 | Volume 5 | Issue 9 | e12647Figure 2. Top 50 best fits of WIHS empiric survival for CD4 50–199/ml and CD4 ,50/ml. Part A of Figure 2 illustrates the top 50 best fits of
the empiric survival data for CD4 50–199/ml. Nearly all runs in the top 50 combined changes in both ‘clinical effectiveness’ of HAART (a function of
regimen efficacy, side effects or toxicity, adherence, and personal choice to remain on HAART) and estimates of CD4 gains while on effective HAART.
The majority of the 50 best fits had a 2- to 3-fold increase in the rates of failure/switching/discontinuation of early lines of HAART in combination with
an increase of 40%–75% in treatment efficacy in later lines of HAART. Part B of Figure 2 illustrates the top 50 best fits of the empiric survival data for
CD4 ,50/ml. Nearly all runs in the top 50 combined changes in both ‘clinical effectiveness’ of treatment (a function of regimen efficacy, side effects or
toxicity, adherence, and personal choice to remain on HAART) and estimates of CD4 gains while on effective HAART. The majority of the 50 best fits
had a 2- to 3-fold increase in the rates of failure/switching/discontinuation of early lines of HAART in combination with an increase of 30%–75% in
treatment efficacy in later lines of HAART.
doi:10.1371/journal.pone.0012647.g002
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The life expectancy projected by the cohort-specific model
calibrated to the 24-month short-term data (using the mean of the
50 best-fitting sets) was 140.9 months (range, 130.5–148.4) among
the patients with CD4 50–199/ml and 80.1 months (range, 65.9–
87.3) among those with CD4 ,50/ml assuming a mean cohort age
of 34 years. The most influential variable on long-term outcomes
in our simulation of the WIHS cohort was the probability of ‘‘late
treatment failure,’’ defined as the monthly probability of treatment
failure after initially successful virologic suppression. Figure 3,
Part A, shows the impact of varying our base case assumptions
(probability of late failure, 0.021) from no late failure to a 2-fold
increase in late failure. Depending on the baseline CD4 cell count,
life expectancy was increased by 14.8 to 30.9 months with no late
failure, and was decreased by 2.8 to 6.6 months with a 1.5-fold
increase in late failure, and by 5.1 to 11.0 months with a 2-fold
increase in late failure.
Figure 3, Part B, shows that when simulating the WIHS
cohort, the incremental gains provided by 5 lines of HAART
compared to 4 lines were greater using the calibrated model. To
estimate the life expectancy that would be expected in HIV-
infected women today in the U.S., we used the calibrated natural
history model to superimpose contemporary treatment strategies
utilizing sequential lines of highly efficacious HAART. Assump-
tions made about efficacy and tolerability of contemporary
HAART are provided in Supporting Information S1.
[46–48,52–55,59–63] Projected life-expectancy in HIV-infected
women on contemporary regimens that are currently available
ranged from 133.1 to 188.7 months given 4 lines of therapy, and
137.3 to 196.4 months given 5 lines of therapy, depending on the
CD4 cell count and assuming a mean cohort age of 34 years
(Figure 3, Part B, embedded table).
Discussion
This paper provides a description of the initial iterative process
we utilized to assess model performance and gain insight about the
generalizability of analyses relying on data derived from particular
study cohorts.
Model-estimated survival of the WIHS all-female cohort using
natural history input parameters derived from the MACS all-male
cohort underestimated survival for individuals with initial CD4 cell
counts ,350/ml, particularly as follow-up time increased. Using
data from the WIHS, coupled with moderate changes in mortality
for those with a history of OI for the two highest CD4 strata, the
re-parameterized model closely approximated the empiric data,
demonstrating good internal consistency. While the differences
between model survival estimates using MACS versus WIHS-
derived parameter values could theoretically reflect gender
differences in natural history, prior data suggests that cohort
differences distinct from gender, such as underlying differences in
general health status and co-morbidities are more likely to explain
differences in estimates.[2–4,31–35,38–40]
Comparison of model-estimated survival of women on HAART
with empiric WIHS survival data showed the model overestimated
short-term survival. Adjustment of influential treatment assump-
tions (e.g., ‘clinical effectiveness’, the ART effect and the CD4 gain
on treatment) individually across all lines of HAART did not
produce a good fit to either 12- or 24-month survival. In contrast,
scenarios that reduced the ‘clinical effectiveness’ of earlier
treatment regimens and increased that of later regimens (e.g.,
3
rd and 4
th line HAART), more closely approximated the empiric
published data. Further, multi-way sensitivity analyses that
simultaneously varied these assumptions allowed less extreme
(and more plausible) changes in individual variables while
providing better visual fits to the published data.
Examination of the good-fitting parameter sets to the empiric
data revealed several interesting observations. First, for both CD4
count strata, good fits to the data required that the ‘clinical
effectiveness’ of 1
st and 2
nd line HAART be reduced such that the
‘‘implied failure rates’’ were 2.0 to 3.5 fold higher. Importantly, as
described above, we considered ‘clinical effectiveness’ as a proxy
for the net impact of regimen efficacy, tolerance without major
toxicity, adherence, and personal choice to remain on treatment.
Accordingly, the ‘‘implied failure rate’’ associated with the model
calibrated to the WIHS cohort serves as a proxy for virologic
failure, toxicity or side effects leading to a change in regimen, and
discontinuation of HAART for undocumented reasons. In
contrast, for both CD4 count strata, best fits to the data were
obtained with a 40% to 60% increase in the effectiveness of 3
rd
and 4
th line HAART, with analogously lower failure/discontin-
uation rates.
The more than 50% reduction in ‘clinical effectiveness’ that
characterized the best fitting parameter sets is inconsistent with the
higher treatment efficacy documented in more recent studies,
[46–48,52–55,59–63] the data used in this exercise were based on
a specific cohort from 1998 and 2002 and would not be expected
to reflect more recent care patterns and improved outcomes.
Further, while we used intention to treat efficacy data from clinical
trials for our initial parameterization, the proportion who choose
Table 2. Comparison of model-generated estimates of HAART regimen ‘switching’ versus published data.
Estimated ‘‘switching’’ in the model calibrated to
the WIHS cohort
Estimated ‘‘switching’’ in the baseline
model
Functional definition of ‘‘switching’’ Switch to a different HAART regimen, any drug change,
discontinuation, or switch to a less intense therapy
Switch to a different HAART regimen or any single
drug change in current HAART regimen
Kirstein et al* Model{ Kirstein et al* Model{
Percent switched in 1 year 65% 65.8% 21.4%–45.6% 25%–45.25%
HAART = highly active antiretroviral therapy; WIHS = Women’s Interagency HIV Study.
*Extracted from ‘‘Timing and Characteristics of Switching HAART Regimens in WIHS between 1994 and 2000’’ (Kirstein et al. JAIDS 2002).[34]
{Average of 50 best-fitting parameter sets weighted by CD4 cell distribution.
{Lower bound of 20% represents proportion switching 1
st line HAART due to virologic failure; upper bound of 45.25% represents proportion switching 2
nd line HAART
due to virologic failure plus an assumption that 25% of women with minor toxicity and all women with nonfatal major toxicity require a single drug switch. This
estimate is based on data from Staszewski et al showing that of the 43% who discontinued indinavir plus two nucleoside reverse transcriptase inhibitors for any reason,
11% was due to symptoms such as gastrointestinal effects.[42]
doi:10.1371/journal.pone.0012647.t002
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than in cohort studies such as this one.[42,46–49]
Recognizing that newer data show better tolerated regimens
and higher treatment efficacy, the necessity for such high failure
rates in initial regimens to calibrate the model prompted us to
consider the particularities of this specific cohort, their clinical
histories and past ART experience, as well as their behaviors
including adherence, discontinuation of HAART, and choices
about continued treatment following HAART toxicity. We
concluded that the substantial reduction in ‘clinical effectiveness’
with 1
st and 2
nd line HAART regimens in this historical simulation
could very well be plausible, given that only 16% to 20% of
women were completely ART naı ¨ve prior to HAART initiation;
approximately 80% had some previous exposure to ART through
mono- or combination therapy.[33,34] Furthermore, 44%–48%
of women who initiated treatment had a diagnosis of AIDS,
suggesting very advanced disease. In contrast to the reduction in
‘clinical effectiveness’ for 1
st and 2
nd line HAART required to
calibrate the model to the WIHS, the efficacy of 3
rd and 4
th line
HAART required an increase that ranged from 30% to 75%; this
considerable increase in efficacy is likely attributable to both the
availability of new and more effective treatment regimens and an
increasingly homogeneous group of women more likely to pursue,
adhere to, and continue treatment.
It is notable, although not unusual for the time period, that a
sizable proportion of women in the cohort elected to discontinue
HAART. For example, between April 1997 and September 1997,
when many women had initiated HAART, 45.6% of these women
switched regimens and 18% reported discontinuing HAART (13%
switched to a less intensive regimen and 5% discontinued therapy
completely).[34] By three years later, in September 2000, the
percentage discontinuing therapy completely increased from 5%
to 11.4%.[34] Similar rates of discontinuation have been seen in
both clinical trials and in cohort studies. For example, Staszewski
et al reported 27%–43% discontinuation of HAART unrelated to
efficacy in a clinical trial of indinavir plus two nucleoside reverse
transcriptase inhibitors versus efavirenz plus two nucleoside
reverse transcriptase inhibitors.[42] Hammer reported that the
overall rate of premature discontinuation was 20% in a clinical
trial comparing zidovudine (or stavudine) and lamivudine (28%)
versus indinavir, zidovudine (or stavudine), and lamivudine
(12%).[49] Several cohort studies described a high rate of
discontinuation and short median duration of time on a specific
regimen. Saag et al. described the increasing number of unique
antiretroviral regimens between 1988 and 1998 and a median
duration of a specific regimen of 4 months.[64] Van Roon et al.
reported that 25% of their clinic patients discontinued HAART
within 1 year of initiating therapy.[65] An Italian cohort found
that 36% of men who began HAART modified or discontinued
their initial regimen over a median follow-up time of 11
months.[66] Mocroft et al. estimated that 26% of their patients
initiating HAART modified or discontinued their regimen within
6 months of initiation and that 45% had modified or discontinued
their regimen after a median follow-up time of 14 months.[67]
The life expectancy projected by the model calibrated to the 24-
month short-term cohort-specific data was 140.9 months using the
mean calculated from simulations using the 50 best-fitting
parameter sets (with individual estimates of the 50 best-fits ranging
from 130.5–148.4 months) among the patients with CD4 50–199/
ml. Further, the incremental gains projected by 5 lines of HAART
versus 4 lines of HAART using the empirically calibrated model
(Figure 3, Part B) were twice those predicted by the model prior
to calibration. We also found that uncertain assumptions, such as
late failure, while not influential on short-term outcomes, exerted a
major impact on the predicted life expectancy. While estimates of
life expectancy varied considerably with plausible changes in
uncertain assumptions, the incremental gains associated with
comparing different treatment strategies within a single cohort
varied far less. The implication is that results of incremental cost-
effectiveness analyses, for example those conducted to inform
choices among competing treatment options, may be less affected
by this variation; in contrast, analyses that seek to project long-
term estimates of life expectancy or cost for a population of HIV-
infected persons, may be more variable.
Our analysis has several important limitations. First, this analysis
is not intended to depict a formal empirical calibration process.
Rather, this paper was intended to provide a description of the
‘‘real world’’ iterative process of assessing model performance while
building a simulation model of a complex disease. In addition, we
sought to demonstrate the kind of insights that can be obtained by
this type of exercise while providing a description that is intended to
increase the transparency of a model development phase. Although
we intended to explore the comparative implications of using
WIHS versus MACS cohort data, our primary goal was not to fit
the model to empiric data. In fact, we would not want to use a
model empirically calibrated to older data, reflecting much lower
treatment efficacy, to inform current policy questions that could
contribute to decisions in the future. Furthermore, we recognize
that therearealternative methodsfor samplingthe parameterspace
including utilization of Bayesian methods, random sampling or
complex optimization algorithms. Our guided approach was
chosen after careful consideration of the practical and theoretical
strengths and limitations of these alternatives, given our goal was to
conduct an exploratory exercise; that being said, it is possible we
did not sufficiently explore the entirety of the parameter space.
These exercises can play an important role in characterizing the
effects of key uncertain assumptions, identifying logical inconsis-
tencies, and helping the analyst to understand and describe the
performance of the model.
Second, cohort heterogeneities pose challenges to assessing
model performance in that it is impossible to reflect all patient and
population level differences in any analysis; the availability of data
Figure 3. Impact of alternative assumptions on life expectancy. Results from sensitivity analyses showed that the most influential variable on
long-term outcomes was the probability of late treatment failure. Part A of Figure 3, shows the impact of varying our base case assumptions (0.021)
from no late failure to a 2-fold increase in late failure. Depending on the baseline CD4 cell count, life-expectancy was increased by 14.8 to 30.9
months with no late failure (green), and was decreased by 2.8 to 6.6 months with 1.5-fold increase in late failure (orange), and by 5.1 to 11.0 months
with a 2-fold increase in late failure (red). The magnitude of these changes was similar regardless of whether we assumed 4 lines or 5 lines of HAART.
Part B of Figure 3 shows the impact of 5 lines of HAART versus 4 lines of HAART on life expectancy. The average life expectancy projected by the
model calibrated to the 24-month short-term data (using the mean of the 50 best-fitting sets) was 140.9 months (range, 130.5-148.4 months) among
the patients with CD4 50–199/ml and 80.1 months (range, 65.9–87.3 months) among those with CD4 ,50/ml. Average life-expectancy projected by
the uncalibrated model varied with different assumptions about the ART effect, ranging from 123.3 months (no ART effect) to 156.5 months (ART
effect) in patients with CD4 50–199/ml, and from 73.2 months (no ART effect) to 100.1 months in patients with CD4 ,50/ml (ART effect). Figure 3, Part
B, shows the incremental gains provided by 5 lines of HAART versus 4 lines of HAART were greatest using the calibrated model (green bars), and
lowest using the uncalibrated model assuming no ART eff ect (orange bars).
doi:10.1371/journal.pone.0012647.g003
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cohort remain limited. Some differences between the WIHS
cohort and the clinical trial cohorts used to generate initial
HAART efficacy estimates[42,49] are clear; for example, the
WIHS is all women (versus trials often with more than 80% male),
more than 30% report a history of injection drug use (versus only
10–18% in trials), and nearly two-thirds are black or Hispanic
(versus more than 50% white in many trials).[33,34] Furthermore,
heterogeneities in prior treatment exposure, underlying health
status, patient adherence, and patient preferences about treatment,
could have substantial effects on outcomes which must be taken
into consideration; these and other unknowable factors could have
directly or indirectly contributed to the high rates of switching and
discontinuation of early lines of HAART in women in the WIHS.
For example, toxicities have been reported as an important reason
for discontinuation of therapy,[66] and a study by Ahdieh and
colleagues reported that women were twice as likely as men to
discontinue HAART because of toxicities.[68]
Third, treatment regimens could not be simulated with
complete accuracy. Between the period of April 1996 and
September 1996 there were roughly 13 unique HAART regimens
used in the WIHS, with 25% of women taking the most common
regimen which consisted of zidovudine, lamivudine and indina-
vir.[34] However, by the year 2000, there were 171 unique
HAART regimens reported in the cohort, with fewer than 15% of
women taking the most common regimen of stavudine, lamivudine
and nelfinavir.[34] We attempted to account for HAART era
effects on treatments used by using values representative of
commonly-used regimens for the given time period during which
the WIHS treatment data were collected.[43] However, we
recognize these assumptions were at best approximations of the
actual range of regimens used.
We emphasize that this analysis is not intended to be a
representation of the current treatment environment, where there
have been substantial improvements over time in response to
treatment, both in terms of drug efficacy and reductions in
treatment failure, in addition to decreases in drug toxici-
ty.[59,60,62,63,69] Rather, the purpose of these exercises was to
assess whether the model could produce results consistent with the
data used to parameterize the model (i.e., internal consistency and
validity), and could simulate a specific cohort such that outcomes
were consistent with independent data from that cohort. Using this
same model to simulate access to contemporary treatment strategies
in HIV-infected women in the United States today, we found the
projected life expectancy in women with a mean CD4 cell count of
350/ml, exceeded 250 months (.21 years) given 5 lines of therapy
and assuming initiation of HAART at a CD4 cell count of 350/ml.
Simulations using a higher CD4 cell count threshold for treatment
and/or a greater number of contemporary treatment regimens are
likely to project even longer life expectancies.
Exercises that involve iterative assessment of model perfor-
mance can provide information about the relative influence of
different uncertain assumptions, illuminate unexpected synergies
between parameters, and provide insight into particular hetero-
geneities within and between cohorts. When data are available to
allow for exercises like those described here, they can be used to
assess model performance; descriptive analyses of the process
taken to do so can contribute to a dialogue about different
approaches that are taken by analysts to assess model process and
model structure uncertainty.
Supporting Information
Supporting Information S1 Supplementary tables and figures
referenced in the main text are provided.
Found at: doi:10.1371/journal.pone.0012647.s001 (1.27 MB
PDF)
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